Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Apr 19, 2019 8:36am
136 Views
Post# 29648440

RE:RE:Insider Trades

RE:RE:Insider TradesOn second thought after my am coffee,

It looks like she exercised 30k options from $1.80 and sold 14k shares in the market.

The tax bill on the exercise would be significant so the sales would help cover that.

Meanwhile, Jean-Denis Talon and Paul Pommier exercised 10k options at the same price and did not sell any.

So, this is much ado about nothing.

bfw




bfw wrote: 14k shares.

Not a huge amount but I’m still not impressed.

It seems we have a large amount of shares represented in this board.

I suggest we all vote against management being awarded options this year.

I’m still bullish on the outlook here but tired of these random employees dumping shares at inopportune times.

bfw


thisisriskystuf wrote: Apr 18/19 Apr 18/19 Lafond, Jocelyn Direct Ownership Common Shares 10 - Disposition in the public market -3,600 $7.01 Apr 18/19 Apr 18/19 Lafond, Jocelyn Direct Ownership Common Shares 10 - Disposition in the public market -4,400 $7.05 Apr 18/19 Apr 17/19 Lafond, Jocelyn Direct Ownership Common Shares 10 - Disposition in the public market -3,000 $7.11 Apr 18/19 Apr 17/19 Lafond, Jocelyn Direct Ownership Common Shares 10 - Disposition in the public market -2,000 $7.12




Bullboard Posts